Total neoadjuvant therapy for rectal cancer: a guide for surgeons

被引：18
作者：
Johnson, Garrett G. R. J. [2 ,3 ]
Park, Jason [4 ]
Helewa, Ramzi M. [2 ]
Goldenberg, Benjamin A. [5 ]
Nashed, Maged [6 ]
Hyun, Eric [1 ,2 ]
机构：
[1] Z3037-409 Tache Ave, Winnipeg, MB R2H 2A6, Canada
[2] Univ Manitoba, Dept Surg, Sect Gen Surg, Winnipeg, MB, Canada
[3] Univ Manitoba, Clinician Investigator Program, Winnipeg, MB, Canada
[4] Univ British Columbia, Dept Surg, Vancouver, BC, Canada
[5] Univ Manitoba, Rady Fac Hlth Sci, Dept Internal Med, Sect Med Oncol & Haematol, Winnipeg, MB, Canada
[6] CancerCare Manitoba, Radiat Oncol, Winnipeg, MB, Canada
来源：
CANADIAN JOURNAL OF SURGERY | 2023年 / 66卷 / 02期
关键词：
PREOPERATIVE CHEMORADIOTHERAPY; OPEN-LABEL; CHEMOTHERAPY; MULTICENTER;
D O I：
10.1503/cjs.005822
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
The modern management of rectal cancers continues to evolve. With the release of data from new landmark randomized controlled trials (RAPIDO, PRODIGE-23), total neoadjuvant therapy (TNT) has moved to the forefront of locally advanced rectal cancer treatment and is considered a standard option in selected patients. Total neoadjuvant therapy promises enhanced systemic disease control, better treatment adherence and less time with an ostomy. However, TNT as currently described encompasses a number of different potential treatment options that differ significantly in terms of their radiation dosage, chemotherapy regimen and order of treatments administered. Being familiar with TNT regimens will be important for rectal cancer surgeons to appropriately advocate for their patients and optimize their outcomes. This article serves as a primer for the general surgeon and offers a pragmatic overview of the indications, realistic expected benefits and potential downsides of each TNT regimen.
引用
收藏
页码：E196 / E201
页数：6
相关论文
共 13 条
  • [1] Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial
    Bahadoer, Renu R.
    Dijkstra, Esmee A.
    van Etten, Boudewijn
    Marijnen, Corrie A. M.
    Putter, Hein
    Kranenbarg, Elma Meershoek-Klein
    Roodvoets, Annet G. H.
    Nagtegaal, Iris D.
    Beets-Tan, Regina G. H.
    Blomqvist, Lennart K.
    Fokstuen, Tone
    ten Tije, Albert J.
    Capdevila, Jaume
    Hendriks, Mathijs P.
    Edhemovic, Ibrahim
    Cervantes, Andres
    Nilsson, Per J.
    Glimelius, Bengt
    van de Velde, Cornelis J. H.
    Hospers, Geke A. P.
    [J]. LANCET ONCOLOGY, 2021, 22 (01) : 29 - 42
  • [2] Long-course preoperative chemoradiation versus 5 x 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study
    Cisel, B.
    Pietrzak, L.
    Michalski, W.
    Wyrwicz, L.
    Rutkowski, A.
    Kosakowska, E.
    Cencelewicz, A.
    Spalek, M.
    Polkowski, W.
    Jankiewicz, M.
    Stylinski, R.
    Bebenek, M.
    Kapturkiewicz, B.
    Maciejczyk, A.
    Sadowski, J.
    Zygulska, J.
    Zegarski, W.
    Jankowski, M.
    Las-Jankowska, M.
    Toczko, Z.
    Zelazowska-Omiotek, U.
    Kepka, L.
    Socha, J.
    Wasilewska-Tesluk, E.
    Markiewicz, W.
    Kladny, J.
    Majewski, A.
    Kapuscinski, W.
    Suwinski, R.
    Bujko, K.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (08) : 1298 - 1303
  • [3] Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23) : a multicentre, randomised, open-label, phase 3 trial
    Conroy, Thierry
    Bosset, Jean-Francois
    Etienne, Pierre-Luc
    Rio, Emmanuel
    Francois, Eric
    Mesgouez-Nebout, Nathalie
    Vendrely, Veronique
    Artignan, Xavier
    Bouche, Olivier
    Gargot, Dany
    Boige, Valerie
    Bonichon-Lamichhane, Nathalie
    Louvet, Christophe
    Morand, Clotilde
    de la Fouchardiere, Christelle
    Lamfichekh, Najib
    Juzyna, Beata
    Jouffroy-Zeller, Claire
    Rullier, Eric
    Marchal, Frederic
    Gourgou, Sophie
    Castan, Florence
    Borg, Christophe
    [J]. LANCET ONCOLOGY, 2021, 22 (05) : 702 - 715
  • [4] Fokas Emmanouil, 2019, J Clin Oncol, V37, P3212, DOI 10.1200/JCO.19.00308
  • [5] A rectal cancer organoid platform to study individual responses to chemoradiation
    Ganesh, Karuna
    Wu, Chao
    O'Rourke, Kevin P.
    Szeglin, Bryan C.
    Zheng, Youyun
    Sauve, Charles-Etienne Gabriel
    Adileh, Mohammad
    Wasserman, Isaac
    Marco, Michael R.
    Kim, Amanda S.
    Shady, Maha
    Sanchez-Vega, Francisco
    Karthaus, Wouter R.
    Won, Helen H.
    Choi, Seo-Hyun
    Pelossof, Raphael
    Barlas, Afsar
    Ntiamoah, Peter
    Pappou, Emmanouil
    Elghouayel, Arthur
    Strong, James S.
    Chen, Chin-Tung
    Harris, Jennifer W.
    Weiser, Martin R.
    Nash, Garrett M.
    Guillem, Jose G.
    Wei, Iris H.
    Kolesnick, Richard N.
    Veeraraghavan, Harini
    Ortiz, Eduardo J.
    Petkovska, Iva
    Cercek, Andrea
    Manova-Todorova, Katia O.
    Saltz, Leonard B.
    Lavery, Jessica A.
    DeMatteo, Ronald P.
    Massague, Joan
    Paty, Philip B.
    Yaeger, Rona
    Chen, Xi
    Patil, Sujata
    Clevers, Hans
    Berger, Michael F.
    Lowe, Scott W.
    Shia, Jinru
    Romesser, Paul B.
    Dow, Lukas E.
    Garcia-Aguilar, Julio
    Sawyers, Charles L.
    Smith, J. Joshua
    [J]. NATURE MEDICINE, 2019, 25 (10) : 1607 - +
  • [6] Garcia-Aguilar J, 2020, J CLIN ONCOL, V38
  • [7] Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial
    Garcia-Aguilar, Julio
    Chow, Oliver S.
    Smith, David D.
    Marcet, Jorge E.
    Cataldo, Peter A.
    Varma, Madhulika G.
    Kumar, Anjali S.
    Oommen, Samuel
    Coutsoftides, Theodore
    Hunt, Steven R.
    Stamos, Michael J.
    Ternent, Charles A.
    Herzig, Daniel O.
    Fichera, Alessandro
    Polite, Blase N.
    Dietz, David W.
    Patil, Sujata
    Avila, Karin
    [J]. LANCET ONCOLOGY, 2015, 16 (08) : 957 - 966
  • [8] cT3N0 rectal cancer: Potential overtreatment with Preoperative chemoradiotherapy is warranted
    Guillem, Jose G.
    Diaz-Gonzalez, Juan A.
    Minsky, Bruce D.
    Valentini, Vincenzo
    Jeong, Seung-Yong
    Rodriguez-Bigas, Miguel A.
    Coco, Claudio
    Leon, Rebecca
    Hernandez-Lizoain, Jose L.
    Aristu, Jose J.
    Riedel, Elyn R.
    Nitti, Donato
    Wong, W. Douglas
    Pucciarelli, Salvatore
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (03) : 368 - 373
  • [9] Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR)
    Jin, Jing
    Tang, Yuan
    Hu, Chen
    Jiang, Li-Ming
    Jiang, Jun
    Li, Ning
    Liu, Wen-Yang
    Chen, Si-Lin
    Li, Shuai
    Lu, Ning-Ning
    Cai, Yong
    Li, Yong-Heng
    Zhu, Yuan
    Cheng, Guang-Hui
    Zhang, Hong-Yan
    Wang, Xin
    Zhu, Su-Yu
    Wang, Jun
    Li, Gao-Feng
    Yang, Jia-Lin
    Zhang, Kuan
    Chi, Yihebali
    Yang, Lin
    Zhou, Hai-Tao
    Zhou, Ai-Ping
    Zou, Shuang-Mei
    Fang, Hui
    Wang, Shu-Lian
    Zhang, Hai-Zeng
    Wang, Xi-Shan
    Wei, Li-Chun
    Wang, Wen-Ling
    Liu, Shi-Xin
    Gao, Yuan-Hong
    Li, Ye-Xiong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (15) : 1681 - +
  • [10] Total Neoadjuvant Therapy (TNT) versus Standard Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis
    Liu, Shuang
    Jiang, Ting
    Xiao, Lin
    Yang, Shanfei
    Liu, Qing
    Gao, Yuanhong
    Chen, Gong
    Xiao, Weiwei
    [J]. ONCOLOGIST, 2021, 26 (09) : E1555 - E1566
12